NHS missing out on cancer drug payments
Cost-sharing schemes for expensive new drugs are becoming increasingly common
The NHS may be missing out on millions of pounds of reimbursement for cancer drugs because of onerous paperwork, say researchers.
Schemes to share the cost of expensive new drugs with pharmaceutical companies are becoming increasingly common. Yet a survey of 31 English health trusts showed up to 50% of the costs had not been recovered. The Department of Health said it was working to make the schemes as simple as possible. More …